Dupilumab Effective for Up To 1 one year in Kids With AD: Look
Extreme detrimental events remained uncommon and pores and skin remained largely optimistic in kids handled with dupilumab (Dupixent) for moderate-to-severe atopic dermatitis (AD) for up to 52 weeks in a section 3 starting up-price extension trial, researchers reported. At 1…